Facioscapulohumeral

VANCOUVER, British Columbia, July 11, 2023 (GLOBE NEWSWIRE) -- SOLVE FSHD, a venture philanthropy organization catalyzing innovation and removing barriers to accelerate new therapies for…

– REACH is the first Phase 3 trial for this rare, progressive, and debilitating muscular disease –– Losmapimod is an oral small molecule that has the potential to be the first therapy to…

Event to discuss unmet need in FSHD, key measures of disease progression and Phase 3 REACH trial Live webcast March 24, 2022 at 10:00am ET CAMBRIDGE, Mass., March 17, 2022 (GLOBE…